Claims

1. A pharmaceutical product comprising (A) a first component which comprises, as an active agent, propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide (Compound I), or a pharmaceutically-acceptable salt thereof; and (B) a second component which comprises, as an active agent, an EGFR inhibitor; as a combined preparation for the simultaneous or sequential use in the treatment of cancer comprising b-Raf having a V600 mutation, wherein the EGFR inhibitor is selected from erlotinib or a pharmaceutically acceptable salt thereof, or cetuximab.

2. The pharmaceutical product for use according to claim 1 for the treatment of colorectal cancer, melanoma and thyroid cancer, comprising b-Raf having the V600E mutation.

3. The pharmaceutical product for use according to any one of claims 1 and 2, further comprising a third component (C), which comprises as an active agent a topoisomerase inhibitor, wherein said topoisomerase inhibitor is irinotecan, or a pharmaceutically acceptable salt thereof.

4. The pharmaceutical product for use according to any one of claims 1 to 3 wherein propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically-acceptable salt thereof, is in amorphous or substantially amorphous form.

5. A kit comprising: (A) a first component which comprises, as an active agent, propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically-acceptable salt thereof; and (B) a second component which comprises, as an active agent, an EGFR inhibitor wherein the EGFR inhibitor is selected from erlotinib or a pharmaceutically acceptable salt thereof, or cetuximab.

6. A kit according to claim 5 further comprising a third component which comprises, as an active agent, irinotecan.

7. A kit according to claims 5 or 6, for use in the treatment of cancer comprising b-Raf having the V600E mutation.

8. The pharmaceutical product for use according to claim 1, wherein said propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo [2,3-b] pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically acceptable salt thereof, is administered twice daily in an amount of from about 850 mg to about 1050 mg; and said erlotinib, or a pharmaceutically acceptable salt thereof, is administered daily in an amount of from about 100 mg to about 200 mg.

9. The pharmaceutical product for use according to claim 1, wherein said propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo [2,3-b] pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically acceptable salt thereof, is administered twice daily in an amount of from about 850 mg to about 1050 mg; and said cetuximab is administered weekly with the first administration being in an amount of from about 400 mg/m^2 to about 500 mg/m^2 and each subsequent administration being in an amount of from about 200 mg/m^2 to about 300 mg/m^2.

10. The pharmaceutical product for use according to claims 8 and 9, further comprising irinotecan, or a pharmaceutically acceptable salt thereof.

11. The pharmaceutical product for use according to claim 10, wherein said irinotecan, or a pharmaceutically acceptable salt thereof, is administered weekly in an amount of from about 50 mg/m^2 to about 200 mg/m^2.

12. The pharmaceutical product for use according to claim 10, wherein irinotecan, or a pharmaceutically acceptable salt thereof, is administered in a six-week cycle at about 75 to about 175 mg/m^2 weekly for the first four weeks.

13. The pharmaceutical product for use according to claim 10, wherein irinotecan, or a pharmaceutically acceptable salt thereof, is administered once every three weeks at about 300 to about 400 mg/m^2; or once every two weeks at about 130 to about 230 mg/m^2.

14. A pharmaceutical product comprising (A) a first component which comprises, as an active agent, Compound I or a pharmaceutically-acceptable salt thereof; and (B) a second component which comprises, as an active agent, erlotinib or a pharmaceutically acceptable salt thereof, as a combined preparation for simultaneous or sequential use in the treatment of cancer comprising b-Raf having the V600E mutation, wherein

(A) is administered in an amount of from about 200 mg/day to about 3000 mg/day, from about 1000 mg/day to about 2500 mg/day, from about 1700 mg/day to about 2100 mg/day or about 1920 mg/day, and (B) is administered in an amount of from about 20 mg/day to about 500 mg/day, from about 100 mg/day to about 400 mg/day, or from about 100 mg/day to about 200 mg/day.

15. A pharmaceutical product comprising (A) a first component which comprises, as an active agent, Compound I, or a pharmaceutically-acceptable salt thereof; and (B) a second component which comprises, as an active agent, cetuximab; as a combined preparation for simultaneous or sequential use in the treatment of cancer comprising b-Raf having the V600E mutation, wherein

(A) is administered in an amount of from about 200 mg/day to about 3000 mg/day, from about 1000 mg/day to about 2500 mg/day, from about 1700 mg/day to about 2100 mg/day or about 1920 mg/day; and (B) is administered in an amount of from about 50 mg/m^2/week to about 700 mg/m^2/week, from about 100 mg/m^2/week to about 600 mg/m^2/week, or from about 200 mg/m^2/week to about 500 mg/m^2/week.

16. A pharmaceutical product comprising (A) a first component which comprises, as an active agent, Compound I or a pharmaceutically-acceptable salt thereof; (B) a second component which comprises, as an active agent, cetuximab; and (C) a third component which comprises, as an active agent, irinotecan or a pharmaceutically-acceptable salt thereof; as a combined preparation for simultaneous or sequential use in the treatment of cancer comprising b-Raf having the V600E mutation, wherein

(A) is administered in an amount of from about 200 mg/day to about 3000 mg/day, from about 1000 mg/day to about 2500 mg/day, from about 1700 mg/day to about 2100 mg/day or about 1920 mg/day;

~~(B) is administered in an amount of from about 50 mg/m^2/week to about 700 mg/m^2/week, from about 100 mg/m^2/week to about 600 mg/m^2/week, or from about 200 mg/m^2/week to about 500 mg/m^2/week; and~~

~~(C) is administered in an amount of from about 1 to about 250 mg/m^2/week, about 50 to about 200 mg/m^2/week, or about 125 mg/m^2/week.~~

Claims

~~1~~1. ~~The u~~Use of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo [2,3-b] pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide , or a pharmaceutically-acceptable salt thereof, and an EGFR inhibitor for the manufacture of medicaments for the treatment of cancer, comprising b-Raf having a V600 mutation, wherein the EGFR inhibitor is selected from erlotinib or a pharmaceutically acceptable salt thereof, or cetuximab.

2. The use according to claim 1 for the treatment of colorectal cancer, melanoma and thyroid cancer, comprising b-Raf having the V600E mutation.

3. The use according to claim 1 or 2, further comprising a third component (C), which comprises as an active agent a topoisomerase inhibitor, wherein said topoisomerase inhibitor is irinotecan, or a pharmaceutically acceptable salt thereof.

4. The use according to any one of the preceding claims, wherein propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo [2,3-b] pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically-acceptable salt thereof, is in amorphous or substantially amorphous form.

5. The use according to any one of the preceding claims, wherein said propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo [2,3-b] pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically acceptable salt thereof, is to be administered twice daily in an amount of from about 850 mg to about 1050 mg; and said erlotinib, or a pharmaceutically acceptable salt thereof, is to be administered daily in an amount of from about 100 mg to about 200 mg.

6. The use according to any one of the preceding claims, wherein said propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo [2,3-b] pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically acceptable salt thereof, is to be administered twice daily in an amount of from about 850 mg to about 1050 mg; and said cetuximab is to be administered weekly with the first administration being

in an amount of from about 400 mg/m^2 to about 500 mg/m^2 and each subsequent administration being in an amount of from about 200 mg/m^2 to about 300 mg/m^2.

7. The use according to claims 5 or 6, further comprising irinotecan, or a pharmaceutically acceptable salt thereof.

8. The use according to claim 7, wherein said irinotecan, or a pharmaceutically acceptable salt thereof, is to be administered weekly in an amount of from about 50 mg/m^2 to about 200 mg/m^2.

9. The use according to claim 7, wherein irinotecan, or a pharmaceutically acceptable salt thereof, is to be administered in a six week cycle at about 75 to about 175 mg/m^2 weekly for the first four weeks.

10. The use according to claim 7, wherein irinotecan, or a pharmaceutically acceptable salt thereof, is to be administered once every three weeks at about 300 to about 400 mg/m^2; or once every two weeks at about 130 to about 230 mg/m^2.

11. Use of (A) a first component which comprises, as an active agent, Compound I or a pharmaceutically-acceptable salt thereof; and (B) a second component which comprises, as an active agent, erlotinib or a pharmaceutically acceptable salt thereof for the manufacture of medicaments for simultaneous or sequential use in the treatment of cancer comprising b-Raf having the V600E mutation, wherein
(A) is to be administered in an amount of from about 200 mg/day to about 3000 mg/day, from about 1000 mg/day to about 2500 mg/day, from about 1700 mg/day to about 2100 mg/day or about 1920 mg/day, and
(B) is to be administered in an amount of from about 20 mg/day to about 500 mg/day, from about 100 mg/day to about 400 mg/day, or from about 100 mg/day to about 200 mg/day.

12. Use of (A) a first component which comprises, as an active agent, Compound I, or a pharmaceutically-acceptable salt thereof; and (B) a second component which comprises, as an active agent, cetuximab; for the manufacture of medicaments for simultaneous or sequential use in the treatment of cancer comprising b-Raf having the V600E mutation, wherein
(A) is to be administered in an amount of from about 200 mg/day to about 3000 mg/day, from about 1000 mg/day to about 2500 mg/day, from about 1700 mg/day to about 2100 mg/day or about 1920 mg/day; and
(B) is to be administered in an amount of from about 50 mg/m^2/week to about 700 mg/m^2/week, from about 100 mg/m^2/week to about 600 mg/m^2/week, or from about 200 mg/m^2/week to about 500 mg/m^2/week.

13. Use of (A) a first component which comprises, as an active agent, Compound I or a pharmaceutically-acceptable salt thereof; (B) a second component which comprises, as an active agent, cetuximab; and (C) a third component which comprises, as an active agent, irinotecan or a pharmaceutically-acceptable salt thereof; for the manufacture of medicaments for simultaneous or sequential use in the treatment of cancer comprising b-Raf having the V600E mutation, wherein
(A) is to be administered in an amount of from about 200 mg/day to about 3000 mg/day, from about 1000 mg/day to about 2500 mg/day, from about 1700 mg/day to about 2100 mg/day or about 1920 mg/day;
(B) is to be administered in an amount of from about 50 mg/m^2/week to about 700 mg/m^2/week, from about 100 mg/m^2/week to about 600 mg/m^2/week, or from about 200 mg/m^2/week to about 500 mg/m^2/week; and
(C) is to be administered in an amount of from about 1 to about 250 mg/m^2/week, about 50 to about 200 mg/m^2/week, or about 125 mg/m^2/week.

14. Use of (A) a first component which comprises, as an active agent, propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo [2,3-b] pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically-acceptable salt thereof; and (B) a second component which comprises, as an active agent, an EGFR inhibitor wherein the EGFR inhibitor is selected from erlotinib or a pharmaceutically acceptable salt thereof, or cetuximab, for the manufacture of a kit for the treatment of cancer comprising b-Raf having a V600 mutation.

15. The use according to claim 14 further comprising a third component which comprises, as an active agent, irinotecan, in the kit.

***